We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+4.51%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$912M
AUM Growth
+$112M
(+14%)
Cap. Flow
+$107M
Cap. Flow
% of AUM
11.78%
Top 10 Holdings %
Top 10 Hldgs %
35.88%
Holding
80
New
13
Increased
28
Reduced
21
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
EXAS
Exact Sciences
EXAS
|
+$18.6M |
| 2 |
ARRY
Array Biopharma Inc
ARRY
|
+$16.5M |
| 3 |
Gilead Sciences
GILD
|
+$16.3M |
| 4 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$13.4M |
| 5 |
ALDR
Alder Biopharmaceuticals
ALDR
|
+$12.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
XLRN
Acceleron Pharma
XLRN
|
+$20.7M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$14.8M |
| 3 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$14.2M |
| 4 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$12.8M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
+$9.64M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
| $51.2M | 5.62% |
3,405,541
+554,772
| +19% | +$8.44M |
|
|
APLS
2
DELISTED
Apellis Pharmaceuticals
APLS
| $36.4M | 3.99% |
1,647,692
-104,963
| -6% | -$2.06M |
|
|
LJPC
3
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $33.6M | 3.68% |
1,128,219
+273,918
| +32% | +$8.83M |
|
4
BioMarin Pharmaceuticals
BMRN
$11.5B
| $32.3M | 3.54% |
397,903
+139,400
| +54% | +$12M |
|
5
Collegium Pharmaceutical
COLL
$1.17B
| $31.6M | 3.46% |
1,236,534
-190,328
| -13% | -$4.53M |
|
|
AERI
6
DELISTED
Aerie Pharmaceuticals
AERI
| $29.2M | 3.2% |
538,618
+169,821
| +46% | +$9.5M |
|
7
Novartis
NVS
$293B
| $28.7M | 3.15% |
396,510
-22,544
| -5% | -$1.72M |
|
8
Pfizer
PFE
$143B
| $28.5M | 3.13% |
847,705
-69,353
| -8% | -$2.38M |
|
9
Johnson & Johnson
JNJ
$609B
| $28.3M | 3.1% |
220,948
+6,599
| +3% | +$892K |
|
|
CELG
10
DELISTED
Celgene Corp
CELG
| $27.3M | 2.99% |
306,130
+74,300
| +32% | +$7.13M |
|
11
Teladoc Health
TDOC
$1.7B
| $26.1M | 2.86% |
646,828
-34,800
| -5% | -$1.31M |
|
12
Sarepta Therapeutics
SRPT
$1.82B
| $24.3M | 2.66% |
327,698
+88,699
| +37% | +$5.91M |
|
|
EXAS
13
DELISTED
Exact Sciences
EXAS
| $23.2M | 2.54% |
574,049
+381,599
| +198% | +$18.6M |
|
|
KTWO
14
DELISTED
K2M Group Holdings, Inc
KTWO
| $23.1M | 2.54% |
1,221,160
+56,748
| +5% | +$1.12M |
|
|
ABMD
15
DELISTED
Abiomed Inc
ABMD
| $22.4M | 2.45% |
76,817
-7,957
| -9% | -$2.02M |
|
16
UnitedHealth
UNH
$387B
| $19.7M | 2.16% |
92,203
+9,299
| +11% | +$2.12M |
|
17
Edwards Lifesciences
EW
$49.4B
| $18.1M | 1.99% |
389,877
-84,423
| -18% | -$3.67M |
|
18
Medtronic
MDT
$106B
| $18M | 1.98% |
224,600
+42,990
| +24% | +$3.55M |
|
19
Abbott
ABT
$175B
| $17.6M | 1.93% |
294,299
-88,610
| -23% | -$5.34M |
|
|
20
Acadia Pharmaceuticals
ACAD
$4.38B
| $17.6M | 1.93% |
783,424
-348,298
| -31% | -$9.64M |
|
|
CLVS
21
DELISTED
Clovis Oncology, Inc.
CLVS
| $16.9M | 1.86% |
320,799
+138,199
| +76% | +$8.06M |
|
|
ARRY
22
DELISTED
Array Biopharma Inc
ARRY
| $16.8M | 1.85% |
+1,031,650
| New | +$16.5M |
|
|
PTLA
23
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $16.3M | 1.78% |
498,412
-38,002
| -7% | -$1.67M |
|
|
24
Gilead Sciences
GILD
$167B
| $15.5M | 1.69% |
+205,000
| New | +$16.3M |
|
25
Eli Lilly
LLY
$1.05T
| $14.1M | 1.54% |
182,100
+17,900
| +11% | +$1.44M |
|
Similar funds
RIP
CCM
LFWA
FWA
CF
WIM
MW
AFC
Sectoral Asset Management's Q1 2018 Portfolio in Review
As of Q1 2018, Sectoral Asset Management held 80 positions worth $912M, up 14% from $800M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Sectoral Asset Management deployed $107M of net new capital in Q1 2018, opening 13 new positions and adding to 28 existing holdings. Its largest new stake was Array Biopharma Inc: 1,031,650 shares worth $16.8M.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier.
On the sell side, the largest reduction was Acceleron Pharma, an estimated $20.7M trimmed.
- Sectoral Asset Management's largest Q1 2018 buy was Array Biopharma Inc: 1,031,650 shares worth $16.8M.
- Sectoral Asset Management added most to Exact Sciences in Q1 2018, an estimated $18.6M increase.
- Sectoral Asset Management's biggest Q1 2018 reduction was Acceleron Pharma, cutting an estimated $20.7M.
- Sectoral Asset Management fully exited Regeneron Pharmaceuticals in Q1 2018, selling an estimated $14.8M.
- Sectoral Asset Management's ten largest holdings make up 36% of its $912M portfolio in Q1 2018.
- Sectoral Asset Management opened 13 new positions and closed 12 in Q1 2018.
- Sectoral Asset Management's portfolio value rose 14% quarter-over-quarter to $912M.
Based on Sectoral Asset Management's 13F filing for Q1 2018, filed 15 May 2018.